Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Heart Failure | Research article

Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea

Authors: Jae-Hyung Roh, Jae-Hyeong Park, Hanbyul Lee, Yong-Hoon Yoon, Minsu Kim, Yong-Giun Kim, Gyung-Min Park, Jae-Hwan Lee, In-Whan Seong

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

Heart failure (HF) is relatively common cardiovascular disease with high mortality and morbidity. Although it is associated with many cardiovascular risk factors, the association between nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease, and HF has not been evaluated in a large-scale cohort study. Thus, we evaluated the ability of the fatty liver Index (FLI), a surrogate marker of NAFLD, to predict the development of HF in healthy individuals.

Methods

We analyzed the association between the FLI and new-onset HF with multivariate Cox proportional-hazards models in 308,578 healthy persons without comorbidities who underwent the National Health check-ups in the republic of Korea from 2009 to 2014.

Results

A total of 2532 subjects (0.8%) were newly diagnosed with HF during the study period (a median of 5.4 years). We categorized our subjects into quartile groups according to FLI (Q1, 0–4.9; Q2, 5.0–12.5; Q3, 12.6–31.0; and Q4, > 31.0). The cumulative incidence of HF was significantly higher in the highest FLI group than in the lowest FLI group (Q1, 307 [0.4%] and Q4, 890 [1.2%]; P < 0.001). Adjusted hazard ratio (HRs) indicated that the highest FLI group was independently associated with an increased risk for HF (HR between Q4 and Q1, 2.709; 95% confidence interval = 2.380–3.085; P < 0.001). FLI was significantly associated with an increased risk of new-onset HF regardless of their baseline characteristics.

Conclusions

Higher FLI was independently associated with increased risk of HF in a healthy Korean population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.CrossRef Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.CrossRef
2.
go back to reference McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–55.CrossRef McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–55.CrossRef
3.
go back to reference Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.CrossRef Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.CrossRef
4.
go back to reference Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54.CrossRef Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54.CrossRef
5.
go back to reference Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97 e10.CrossRef Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97 e10.CrossRef
6.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRef
7.
go back to reference Lee JH, Kim MS, Kim EJ, Park DG, Cho HJ, Yoo BS, et al. KSHF guidelines for the Management of Acute Heart Failure: part I. definition, epidemiology and diagnosis of acute heart failure. Korean Circ J. 2019;49:1–21.CrossRef Lee JH, Kim MS, Kim EJ, Park DG, Cho HJ, Yoo BS, et al. KSHF guidelines for the Management of Acute Heart Failure: part I. definition, epidemiology and diagnosis of acute heart failure. Korean Circ J. 2019;49:1–21.CrossRef
8.
go back to reference Lee JH, Lim NK, Cho MC, Park HY. Epidemiology of heart failure in Korea: present and future. Korean Circ J. 2016;46:658–64.CrossRef Lee JH, Lim NK, Cho MC, Park HY. Epidemiology of heart failure in Korea: present and future. Korean Circ J. 2016;46:658–64.CrossRef
9.
go back to reference Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34:2804–11.CrossRef Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34:2804–11.CrossRef
10.
go back to reference Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart failure and liver disease: Cardiohepatic interactions. JACC Heart Fail. 2019;7:87–97.CrossRef Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart failure and liver disease: Cardiohepatic interactions. JACC Heart Fail. 2019;7:87–97.CrossRef
11.
go back to reference Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425–39.CrossRef Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425–39.CrossRef
12.
go back to reference Zhang Z, Wang P, Guo F, Liu X, Luo T, Guan Y, et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. J Int Med Res. 2018;46:3959–69.CrossRef Zhang Z, Wang P, Guo F, Liu X, Luo T, Guan Y, et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. J Int Med Res. 2018;46:3959–69.CrossRef
13.
go back to reference Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC). South Korea Int J Epidemiol. 2017;46:e15.PubMed Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC). South Korea Int J Epidemiol. 2017;46:e15.PubMed
14.
go back to reference Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.CrossRef Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.CrossRef
15.
go back to reference Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.CrossRef Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.CrossRef
16.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.CrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.CrossRef
17.
go back to reference Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One. 2015;10:e0120443.CrossRef Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One. 2015;10:e0120443.CrossRef
18.
go back to reference Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB Sr, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30:1855–60.CrossRef Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB Sr, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30:1855–60.CrossRef
19.
go back to reference Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32:830–5.CrossRef Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32:830–5.CrossRef
20.
go back to reference Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Antikainen R, et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99:163–7.CrossRef Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Antikainen R, et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99:163–7.CrossRef
21.
go back to reference Jung JY, Park SK, Ryoo JH, Oh CM, Kang JG, Lee JH, et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol Res. 2017;47:522–32.CrossRef Jung JY, Park SK, Ryoo JH, Oh CM, Kang JG, Lee JH, et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol Res. 2017;47:522–32.CrossRef
22.
go back to reference Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol. 2016;221:275–9.CrossRef Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol. 2016;221:275–9.CrossRef
23.
go back to reference Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, et al. Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension. 2004;43:1324–31.CrossRef Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, et al. Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension. 2004;43:1324–31.CrossRef
24.
go back to reference Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117–25.CrossRef Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117–25.CrossRef
25.
go back to reference Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension? Lancet. 1987;2:435–7.CrossRef Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension? Lancet. 1987;2:435–7.CrossRef
26.
go back to reference Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87:497–9.CrossRef Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87:497–9.CrossRef
27.
go back to reference Sigala B, McKee C, Soeda J, Pazienza V, Morgan M, Lin CI, et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS One. 2013;8:e72928.CrossRef Sigala B, McKee C, Soeda J, Pazienza V, Morgan M, Lin CI, et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS One. 2013;8:e72928.CrossRef
28.
go back to reference Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci (Lond). 2007;113:109–18.CrossRef Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci (Lond). 2007;113:109–18.CrossRef
29.
go back to reference Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64:924–8.CrossRef Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64:924–8.CrossRef
30.
go back to reference Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–52.CrossRef Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–52.CrossRef
31.
go back to reference Takahashi T, Watanabe T, Shishido T, Watanabe K, Sugai T, Toshima T, et al. The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure. Heart Vessel. 2018;33:733–9.CrossRef Takahashi T, Watanabe T, Shishido T, Watanabe K, Sugai T, Toshima T, et al. The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure. Heart Vessel. 2018;33:733–9.CrossRef
32.
go back to reference Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, et al. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018;265:162–8.CrossRef Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, et al. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018;265:162–8.CrossRef
33.
go back to reference Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.CrossRef Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.CrossRef
34.
go back to reference VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62:773–83.CrossRef VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62:773–83.CrossRef
35.
go back to reference Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Valbusa F, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism. 2015;64:879–87.CrossRef Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Valbusa F, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism. 2015;64:879–87.CrossRef
36.
go back to reference Valentova M, von Haehling S, Doehner W, Murin J, Anker SD, Sandek A. Liver dysfunction and its nutritional implications in heart failure. Nutrition. 2013;29:370–8.CrossRef Valentova M, von Haehling S, Doehner W, Murin J, Anker SD, Sandek A. Liver dysfunction and its nutritional implications in heart failure. Nutrition. 2013;29:370–8.CrossRef
37.
go back to reference Sawyer DB. Oxidative stress in heart failure: what are we missing? Am J Med Sci. 2011;342:120–4.CrossRef Sawyer DB. Oxidative stress in heart failure: what are we missing? Am J Med Sci. 2011;342:120–4.CrossRef
38.
go back to reference Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–42.CrossRef Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–42.CrossRef
Metadata
Title
Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea
Authors
Jae-Hyung Roh
Jae-Hyeong Park
Hanbyul Lee
Yong-Hoon Yoon
Minsu Kim
Yong-Giun Kim
Gyung-Min Park
Jae-Hwan Lee
In-Whan Seong
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01444-x

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue